Amanote Research
Register
Sign In
P68 Asthma Symptom Improvements With Benralizumab Are Associated With Improvements in Activity Functions and Quality of Life for Patients With Severe, Uncontrolled Asthma: Results of Pooled Phase Iii Benralizumab Studies
doi 10.1136/thoraxjnl-2017-210983.210
Full Text
Open PDF
Abstract
Available in
full text
Date
November 15, 2017
Authors
G Gopalan
X Xu
S O’Quinn
I Hirsch
Publisher
BMJ Publishing Group Ltd and British Thoracic Society
Related search
Daily Patient-Reported Health Status Assessment Improvements With Benralizumab for Patients With Severe, Uncontrolled Eosinophilic Asthma
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma
Annals of Allergy, Asthma and Immunology
Respiratory Medicine
Pulmonary
Allergy
Immunology
Pooled Baseline Characteristics of Women in Phase III Benralizumab Asthma Exacerbation Studies (SIROCCO and CALIMA)
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Clinical Pharmacology and Therapeutics
Pharmacology
Benralizumab for the Treatment of Severe Eosinophilic Asthma
Prescriber
Pharmacology
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients With Asthma
Clinical Pharmacokinetics
Pharmacology
Benralizumab: A Unique IL-5 Inhibitor for Severe Asthma
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients With Severe Eosinophilic Asthma
Advances in Therapy
Medicine
Pharmacology
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
